BusinessMateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint InhibitorsBy Nasdaq OMXJun 28, 2017, 11:30 AM UTC
BusinessHistogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage DamageBy Nasdaq OMXJun 27, 2017, 8:01 PM UTC
BusinessNeothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous FatBy Nasdaq OMXJun 26, 2017, 12:01 PM UTC
BusinessPositive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, SpaiBy Nasdaq OMXJun 23, 2017, 11:00 AM UTC
BusinessNoblegen Announces the Opening of Its Second Round of Financing: Peterborough-based biotechnology startup targeting up to $50 million in equity financingBy Nasdaq OMXJun 22, 2017, 5:22 PM UTC
BusinessBurcon Announces Fiscal 2017 Results and Reviews OperationsBy Nasdaq OMXJun 21, 2017, 8:26 PM UTC
BusinessPatent for Reducing Inflammatory Response Granted to Galectin TherapeuticsBy Nasdaq OMXJun 21, 2017, 12:30 PM UTC
BusinessAdverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chief Medical OfficerBy Nasdaq OMXJun 20, 2017, 1:00 PM UTC
